Posts Tagged ‘David Kappos’

PTO Proposes Simplified Appeal Process – Compared to What?

Tuesday, November 16th, 2010

On November 15th, Director Kappos published 21 pages of proposed rulemaking entitled “Rules of Practice Before the [BPAI] in Ex parte Appeals.” 75 Fed. Reg. 69828 (Nov. 15, 2010). (A copy is available at the end of this post.) There is an entire column of “Background” which summarizes the fate of the rule changes first proposed on July 30, 2007, widely criticized, never implemented, currently stayed and now proposed to be rescinded in favor of these new proposed rules. The new rules have two main thrusts: to simply the briefing process and to get the appeal before the Board more quickly (and to keep it there).

To provide some context, I filed an Appeal Brief under the rules then in effect on Oct. 12, 2007, the Examiner filed an answer in January 2009 and I filed a Reply in February 2009. The application was not forwarded to the Board and docketed until January 2010 (!) Most of the delay was apparently caused by the Examiner’s failure to list one piece of art in the “evidence relied upon” section of his Answer. The new rules intend to prevent this sort of delay by transmitting the appeal to the Board after the Reply is received (and the Examiner would not be able to respond to the Reply Brief). The Board has the sole authority to determine non-compliance but would not be able to remand an application to the Examiner without the Director’s approval. There are many other changes, too numerous to “reprint” here, but some stuck in my head after reading most of the notice.

Preparation of the Brief is simplified somewhat by not requiring a statement of the detailed history of the claims on appeal, not requiring that support be given for every claim limitation in the independent claims – only those in dispute — and by omitting the requirement for the “claims appendix” and the “evidence appendix.” The Board is to presume that the appeal is taken from all claims under rejection, even if appellant fails to list them all. The options if the Examiner enters a new ground of rejection are clarified (I think), as well as the required statement of related appeals, interferences and judicial proceedings (I think), and examples of new grounds of rejection are given. The proposed rules make it perfectly clear, however, that substantive prosecution stops after filing the appeal brief (not upon filing the notice of appeal). However, applicants can still send in case law that advances their position. Importantly, the new rules eliminate the “presumption of Examiner correctness” from the rules. For background on this presumption, see 75 Fed. Reg. at 69835.

With the Board currently affirming rejections 65-70% of the time, the new rules, even if they are finalized, may only smooth your prosecution highway to the edge of a cliff, but at least the Director seems well aware that “justice delayed is justice denied.” Now let’s work on the “justice” part a little harder.

75 FedReg at 69835

Director Kappos “Chats” About PTO S.W.O.T.

Thursday, October 21st, 2010

Wednesday noon at the AIPLA 2010 Annual Meeting, USPTO Director David Kappos engaged in a “fireside chat” (actually podium-side chat) with AIPLA Executive Director and former PTO Director Q. Todd Dickinson about the Strengths, Weaknesses, Opportunities and Threats that he has experienced since becoming Director. Regarding the 710,000 application backlog, he stated that his goal was to reduce it to a manageable 325,000, which would provide sufficient work for the current Examining staff, and the 1,000 new Examiners he said he hopes to hire over the next year. Although he did not say when this level would be reached, he also endorsed a goal of 10 months to a first action and 20 months to disposal, with an average of 2, 1 actions per case (it is now about 3 per case).

While Director Kappos endorsed the various proposals and pilot programs for accelerated examination as “important to the applicant community,” Dickinson noted that they are scarcely used at this point. Kappos also endorsed three-tiered examination and felt that the ability to defer examination for 30 months would help reduce the backlog, since applicants would abandon applications without demonstrated value. He noted that the initial proposal to limit access to applications first filed abroad had hit a storm of criticism and that it would be withdrawn or greatly curtailed.

When asked to identify the most important part of the proposed patent reform legislation, he answered “first-to-file” and said that it was his opinion that this change would benefit small entities [ed. note: Even if they don't all seem to realize that yet]. All-in-all an engaging and quite candid “coffee talk” from this very hard-working Director.

Defining the Abstract and Conceptual – USPTO Issues “Guidance” Post-Bilski

Monday, August 2nd, 2010

Before I write another word, I want to recognize and applaud the intellectual and logistical effort it must have taken for Director Kappos and his helpers to put together six pages of “Interim Guidance For Determining Subject Matter Eligibility for Process Claims in View of Bilski v. Kappos,” 75 Fed. Reg. 43922 (July 27, 2010), (attached at end of post) “for its personnel to use when determining subject matter eligibility under U.S.C 101…The Office is especially interested in receiving comments regarding the scope and extent of the holding in Bilski.” The Office deserves our attention.

In my last post, I considered the difficulty in setting standards by which to determine whether or not a claim to a process is an abstract idea or rather does it involve concrete technology. The Interim Guidance (an official “Notice”) tackles this question head on. The Notice cites Chakrabarty as endorsing an expansive view of what constitutes a “new and useful process,” limited by the exceptions “laws of nature, physical phenomena and abstract ideas.” The Notice observes that “the Office had used the ‘abstract idea’ exception in cases where a claimed ‘method’ did not sufficiently recite a physical instantiation…Thus, the Bilski claims were said to be drawn to an ‘abstract idea’ despite the fact that they included steps of initiating transactions. The ‘abstractness’ is in the sense that there are no limitations as to the mechanism for entering into the transactions.” Notice at 93924. (Such limitations create the instantiation, a word I had to look up.)

The Notice discusses, and goes on to outline, four primary factors weighing toward patent eligibility and four primary factors weighing against it. The first step in the “pro” column is the express or inherent recitation of a machine or transformation. Likewise, the first and second “con” steps are no, or insufficient recitation, of a machine or transformation (again, express or inherent). Then it gets interesting. Factor three of the “pro” list is that the claim is directed toward a practical application of a law of nature, that limits the execution of the steps. The “con” factor is that the claim is not directed to the application of a law of nature and would monopolize a natural force or patent a scientific fact. A “con” example might be a claim, not to a diagnostic assay for a vitamin deficiency or cancer, but to the underlying fact that human blood contains certain amounts of homocysteine or PSA.

The fourth “pro” factor begins to cross into even less intellectually stable realms: “The claim is more than a mere statement of a concept.” The “con” factor mirrors it, “The claim is a mere statement of a general concept…use of the concept, as expressed in the method would effectively grant a monopoly over the concept.” But on reflection, these are more practical factors then they might first appear. Every prep/pros practitioner has encountered inventors who want to patent concepts or bright ideas, as opposed to inventions. Such a general concept might be stated as correlating mutations in genes to a propensity to develop cancer. How about “A car that runs on water as fuel.” I once had a professor approach me to patent his idea to develop a pig with organs that would not give rise to a rejection response when transplanted into humans. This was indeed a bright idea, but he had no idea how to create such a pig. This sort of “invention” was so common in the early days of biotechnology, that I wrote in the margins of my copy of Chemical Patent Practice (J. L. White): “You don’t patent ‘concepts’, you patent inventions; e.g., ‘power transfer’ vs. the gears that do it.” BNA PCTJ vol. 34, 264 (1987); Perkin-Elmer Corp. v Westinghouse Electric Corp.” I will leave it to you to check the cites.


bilski_guidance_27jul2010

Director Kappos Comments on Ariad v. Lilly

Thursday, May 6th, 2010

USPTO David Kappos recently posted a comment on the Fed. Cir. decision in Ariad v. Lilly in which he noted that the Fed. Cir. held that broad functional claims (presumably mechanism-of-action claims) must be supported by sufficient species (read “working examples”). While Director Kappos clearly approves of this holding, he does no more to provide guidance to Examiners attempting to decide how many examples will support such claims and, more importantly, are there generic claims for which no number of working examples would provide sufficient support (like the Ariad claims at issue)?